List of Excipients in Branded Drug THIAMINE

Generic Drugs Containing THIAMINE

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	thiamine hydrochloride	50090-4407	CHLOROBUTANOL
A-S Medication Solutions	thiamine hydrochloride	50090-4407	MONOTHIOGLYCEROL
A-S Medication Solutions	thiamine hydrochloride	50090-4407	SODIUM HYDROXIDE
Fresenius Kabi USA LLC	thiamine hydrochloride	63323-013	CHLOROBUTANOL
Fresenius Kabi USA LLC	thiamine hydrochloride	63323-013	MONOTHIOGLYCEROL
Fresenius Kabi USA LLC	thiamine hydrochloride	63323-013	SODIUM HYDROXIDE
Caplin Steriles Limited	thiamine hydrochloride	65145-129	CHLOROBUTANOL HEMIHYDRATE

What are the Most Frequently-Used Excipients in THIAMINE?

# Of NDCs	Excipient
2	CHLOROBUTANOL
3	CHLOROBUTANOL HEMIHYDRATE
5	MONOTHIOGLYCEROL
5	SODIUM HYDROXIDE

Thiamine Excipient Strategy and Commercial Opportunities in Pharmaceutical Formulation

Last updated: July 31, 2026

Thiamine is an off-patent vitamin B1 active ingredient with low active-ingredient barriers and broad formulation flexibility. Commercial value is concentrated in dosage-form performance, stability, taste masking, parenteral quality, combination products, and differentiated derivatives such as benfotiamine. The strongest excipient opportunities are moisture control, oxidation protection, rapid-dissolution tablets, pediatric liquids, injectable systems, and high-dose products for deficiency, alcohol-use disorder, bariatric patients, and parenteral nutrition.

What pharmaceutical forms of thiamine are commercially available?

Thiamine is marketed primarily as thiamine hydrochloride, thiamine mononitrate, and derivative compounds including benfotiamine.

Form	Typical use	Key formulation issue	Commercial position
Thiamine hydrochloride	Tablets, capsules, oral liquids, injections	Moisture sensitivity, solution stability, taste	Main pharmaceutical salt
Thiamine mononitrate	Tablets, capsules, premixes, multivitamins	Lower water solubility, dissolution control	Common in solid oral products
Benfotiamine	High-dose oral products	Poor water solubility, dissolution and bioavailability	Differentiated supplement and pharmaceutical opportunity
Thiamine tetrahydrofurfuryl disulfide	Oral products in selected markets	Lipophilicity, stability, regulatory positioning	Niche derivative
Parenteral thiamine hydrochloride	Injection and infusion products	Sterility, pH, oxidation, particulate control	Hospital and emergency-care segment

Thiamine hydrochloride is listed in U.S. drug labeling for injectable and oral products. Thiamine mononitrate is widely used in dietary supplements, fortified foods, and multivitamin products. The two salts have different solubility and processing profiles, which makes salt selection a central excipient and manufacturing decision.

What excipients are best suited to thiamine tablets and capsules?

Immediate-release solid oral formulations are the largest and lowest-cost opportunity. The objective is usually rapid dissolution, protection from humidity, acceptable tablet hardness, and prevention of discoloration.

Common excipient architecture

Function	Suitable excipient classes	Formulation rationale
Diluent	Microcrystalline cellulose, lactose, mannitol, dicalcium phosphate	Controls tablet weight and compressibility
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid release
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Moisture protection	Film coatings, high-barrier blisters, desiccants	Limits degradation and physical instability
Taste masking	Methacrylate polymers, hypromellose, ion-exchange resins	Relevant to chewables and pediatric dosage forms

Thiamine hydrochloride is relatively water soluble, making it suitable for direct compression or wet granulation when the formulation protects the active from excess moisture and heat. Thiamine mononitrate has lower water solubility and may require particle-size control, wetting agents, or a more aggressive disintegration system.

Mannitol is useful in chewable and orally disintegrating tablets because it provides a cooling mouthfeel and lower hygroscopicity than some polyols. Microcrystalline cellulose and crospovidone are practical choices for low-dose tablets where content uniformity and rapid disintegration are priorities.

Wet granulation can improve blend uniformity in low-dose products, but water exposure must be controlled. Dry granulation or direct compression may reduce processing risk for moisture-sensitive formulations. The preferred process depends on salt form, dose, particle-size distribution, and target release profile.

What formulation patents protect thiamine products?

Core patents on thiamine and conventional thiamine salts have expired. Patent value now tends to reside in formulation architecture, delivery systems, combinations, manufacturing processes, and thiamine derivatives.

Patentable formulation features

Potentially defensible features include:

• A defined thiamine-to-excipient ratio that improves dissolution or stability.
• A moisture-barrier tablet or capsule system.
• A sustained-release matrix for high-dose oral delivery.
• A taste-masked pediatric liquid or chewable formulation.
• A stable sterile injectable composition with a defined pH and antioxidant system.
• A combination product containing thiamine and other B vitamins, minerals, or neurologic agents.
• A formulation using benfotiamine or another lipophilic derivative to improve systemic exposure.
• A multiparticulate or lipid-based delivery system.
• A process that limits degradation during granulation, coating, sterilization, or storage.

Patent protection is more credible when the formulation produces measurable technical effects, such as improved stability, dissolution, bioavailability, reduced injection-site reactions, or superior content uniformity. Claims limited to routine selection of a conventional filler or lubricant are more vulnerable to obviousness challenges.

How should excipients be selected for thiamine injections?

Parenteral thiamine is a higher-value formulation segment because manufacturing, sterility, container closure, and stability requirements create practical barriers beyond the active ingredient.

Thiamine hydrochloride injection products require control of:

• Sterility and bacterial endotoxins.
• Visible and subvisible particles.
• pH and osmolality.
• Oxidative degradation.
• Container interaction.
• Light and temperature exposure.
• Compatibility with infusion fluids and other injectable vitamins.

An injectable formulation may use sodium chloride for isotonicity and a controlled aqueous vehicle. Antioxidant or chelating strategies require careful compatibility assessment because excipients can affect degradation pathways, color, pH, or regulatory acceptability. Preservatives may be relevant to multidose presentations but are less attractive for single-dose hospital products.

The commercial opportunity is strongest in ready-to-use syringes, premixed infusion bags, stable ampoules, and combination parenteral nutrition products. Hospitals place value on reduced preparation time, lower compounding risk, and standardized dosing.

What excipient opportunities exist for pediatric thiamine products?

Pediatric formulations are underserved relative to adult tablets and supplements. The main commercial barriers are taste, dose flexibility, preservative selection, and stability after opening.

High-potential pediatric formats

1. Oral solutions with calibrated dosing devices.
2. Low-volume concentrated liquids.
3. Powder-for-reconstitution products.
4. Taste-masked dispersible tablets.
5. Chewable tablets and mini-tablets.
6. Unit-dose sachets for reconstitution.

Thiamine hydrochloride is better suited than thiamine mononitrate to aqueous liquid products because of its higher solubility. Sweeteners, flavors, viscosity modifiers, and buffering systems must be selected around stability and microbial-control requirements. Benzoate or sorbate preservatives may be considered in multidose liquids, but their use must be compatible with pH and the intended patient population.

Taste masking can create a stronger product position than a conventional liquid. Polymer coating, ion-exchange complexes, or multiparticulate systems can reduce bitterness while preserving rapid release after swallowing.

What commercial opportunities exist in benfotiamine and other thiamine derivatives?

Benfotiamine has a different formulation profile from thiamine hydrochloride. It is more lipophilic and has limited water solubility, creating a need for solubilization and dissolution technologies.

Potential approaches include:

• Micronization or nanomilling.
• Solid dispersions.
• Lipid-based formulations.
• Self-emulsifying drug delivery systems.
• Cyclodextrin complexes.
• Amorphous solid dispersions.
• Surfactant-assisted wetting systems.
• Modified-release matrices.

These technologies can support patent claims when they demonstrate improved exposure, reduced dose variability, or superior dissolution under biorelevant conditions. The commercial opportunity is strongest in high-dose oral products positioned for diabetic neuropathy, nerve health, metabolic disorders, and other indications where conventional thiamine has limited absorption.

Derivative products also carry greater regulatory and patent complexity. A company must separate the regulatory status and evidence base for thiamine from that of benfotiamine. A formulation improvement for benfotiamine does not automatically establish clinical equivalence to a thiamine product.

When does thiamine lose exclusivity?

Thiamine active-ingredient exclusivity has already expired in the United States and other major pharmaceutical markets. Conventional thiamine hydrochloride and thiamine mononitrate products are available from multiple manufacturers and ingredient suppliers.

Exclusivity category	Thiamine status
New chemical entity exclusivity	Expired
Core compound patent	Expired
Conventional salt patent protection	Expired or commercially irrelevant
Generic-drug competition	Established
Supplement competition	Extensive
Formulation patent opportunity	Available for new delivery systems
Regulatory exclusivity for a new thiamine product	Possible only if a qualifying new product or indication meets statutory requirements

The commercial question is therefore not whether thiamine itself is protected. It is whether a formulation, delivery system, combination, manufacturing process, or derivative creates a defensible product position.

What is the FDA regulatory status of thiamine?

Thiamine is regulated across several product categories:

• Prescription injectable drugs.
• Prescription or nonprescription oral drug products, depending on labeling and indication.
• Dietary supplements.
• Food and nutritional fortification products.
• Medical nutrition and parenteral nutrition products.

FDA approval status depends on the dosage form, strength, route, indication, labeling, and manufacturer. The regulatory pathway for a sterile injectable differs materially from the pathway for a supplement or conventional oral product.

Thiamine products may appear in FDA drug-labeling databases and the Orange Book when they are approved drug products with therapeutic-equivalence listings. Many supplement products are outside the Orange Book because they are not approved under the drug-application framework. Orange Book visibility therefore does not provide a complete picture of the thiamine market.

Are there Paragraph IV challenges to thiamine products?

Paragraph IV litigation is not a central risk for conventional thiamine products because the core products are long off-patent and generic competition is established. Paragraph IV exposure would arise mainly from a newer formulation patent, combination product, or derivative product listed in the Orange Book.

A generic applicant could challenge:

• A listed formulation patent.
• A method-of-use patent.
• A controlled-release design.
• A combination-product patent.
• A delivery-system patent.

For a conventional thiamine tablet or capsule, commercial entry risk is driven more by abbreviated approval requirements, manufacturing economics, and supply reliability than by patent litigation.

What manufacturing and intellectual-property barriers affect thiamine?

The strongest practical barriers are operational rather than molecule-based.

Manufacturing barriers

• Low-dose content uniformity.
• Humidity control during blending and compression.
• Degradation during wet granulation.
• Stable sterile filling for injections.
• Color and impurity control.
• Consistent particle-size distribution.
• Compatibility with multivitamin premixes.
• Container-closure protection.
• Long-term stability under accelerated conditions.

Thiamine products are often low-margin commodities. A formulation company can improve economics by reducing process steps, enabling direct compression, using unit-dose packaging, extending shelf life, or supplying ready-to-use hospital products.

Geographic coverage

The active ingredient is globally commoditized, but product requirements vary by jurisdiction. The European Union, United States, Japan, China, and emerging markets differ in classification, permitted claims, excipient standards, supplement rules, and injectable registration requirements. A formulation patent may provide limited commercial protection if the product is sold primarily as a supplement in markets where drug-patent enforcement is not the main competitive constraint.

How strong is the patent estate for thiamine?

The patent estate is weak for conventional thiamine and potentially moderate for engineered delivery systems.

Product strategy	Patent strength	Main commercial defense
Standard thiamine tablet	Low	Cost, supply, distribution
Standard thiamine capsule	Low	Brand and channel access
Thiamine oral liquid	Low to moderate	Taste, stability, pediatric positioning
Sterile ready-to-use injection	Moderate	Manufacturing, quality, hospital contracts
Sustained-release thiamine	Moderate	Release profile and clinical performance
Benfotiamine formulation	Moderate to strong	Bioavailability and formulation claims
Lipid or nanoparticle delivery system	Moderate to strong	Technical effect and process know-how
Combination nutritional product	Low to moderate	Brand, clinical positioning, formulation

Trade secrets may be more valuable than patents in low-margin products. Examples include granulation parameters, coating conditions, impurity-control methods, liquid preservation systems, and validated sterilization cycles.

Which companies are positioned to compete in thiamine products?

Competition comes from several groups:

• Generic pharmaceutical manufacturers supplying thiamine hydrochloride and injection products.
• Multivitamin companies using thiamine mononitrate.
• Contract manufacturers producing tablets, capsules, liquids, and premixes.
• Nutraceutical companies selling benfotiamine.
• Hospital suppliers offering injectable vitamins and parenteral nutrition components.
• Specialty formulation companies developing solubilized or modified-release derivatives.

Licensing opportunities are more likely to involve a delivery platform, branded combination, hospital-ready presentation, or regional distribution rights than a license to thiamine itself. A company with a validated pediatric liquid, stable injectable premix, or high-bioavailability benfotiamine formulation may attract licensing interest despite the absence of active-ingredient exclusivity.

What generic launch scenarios exist for thiamine?

Conventional oral product

Entry is straightforward. The principal risks are price erosion, quality compliance, supply-chain continuity, and retail or institutional access.

Injectable product

Entry is more difficult because of sterile manufacturing, inspection risk, shortage exposure, and hospital procurement requirements. A ready-to-use presentation can command a premium over an ampoule if it reduces preparation and administration costs.

Pediatric liquid

Competition is limited by taste, stability, dosing accuracy, and patient adherence. A differentiated liquid can sustain commercial value even without strong patent protection.

Benfotiamine product

Entry depends on formulation complexity, clinical positioning, and the scope of any active formulation patents. A generic or follow-on product with improved dissolution or exposure could compete against existing products while relying on a distinct excipient system.

What is the revenue exposure for thiamine manufacturers?

Revenue exposure is highest in products with clinical or operational differentiation:

1. Sterile injectable thiamine and parenteral nutrition.
2. Hospital-ready combination products.
3. Pediatric and geriatric liquid formulations.
4. High-dose benfotiamine products.
5. Premium multivitamin and metabolic-health products.
6. Stable premixes for food, feed, and pharmaceutical manufacturing.

Commodity tablets and capsules face substantial price competition. Their value depends on manufacturing scale, reliable sourcing, regulatory compliance, and channel strength. Excipient innovation can improve margins, but only when it lowers total cost or supports a premium product claim.

Key Takeaways

• Thiamine hydrochloride and thiamine mononitrate are off-patent and widely available.
• The best excipient opportunities involve formulation performance rather than active-ingredient protection.
• Moisture control, rapid disintegration, taste masking, and sterile stability are the main technical priorities.
• Pediatric liquids, ready-to-use injections, and parenteral nutrition products offer stronger commercial differentiation than standard tablets.
• Benfotiamine has greater formulation and patent potential because of its poor water solubility and differentiated absorption profile.
• Paragraph IV risk is limited for conventional thiamine but can arise for newer formulation, combination, or derivative products.
• Manufacturing know-how, packaging, quality systems, and hospital distribution may be more valuable than composition patents.
• Licensing opportunities are concentrated in delivery platforms, branded combinations, specialty dosage forms, and regional commercialization rights.

Frequently Asked Questions

Is thiamine hydrochloride more suitable than thiamine mononitrate for oral liquids?

Yes. Thiamine hydrochloride is generally more suitable for aqueous oral liquids because it has higher water solubility. Thiamine mononitrate is more commonly used in solid oral products and premixes.

Can a new thiamine tablet receive patent protection?

Yes, but protection must usually come from a novel formulation, release profile, manufacturing process, combination, or measurable technical effect. A routine tablet containing conventional thiamine and standard excipients is unlikely to support strong patent protection.

Which thiamine product has the greatest commercial potential?

Ready-to-use injectable products, pediatric liquids, high-dose benfotiamine formulations, and stable combination products have greater differentiation potential than standard thiamine tablets.

Are thiamine supplements listed in the Orange Book?

Generally, no. The Orange Book covers approved drug products and therapeutic-equivalence information, while many thiamine supplements are marketed under the dietary-supplement framework.

What is the main regulatory risk for a new thiamine injection?

The principal risks are sterile manufacturing failure, particulate contamination, degradation, container-closure problems, inadequate stability, and incompatibility with infusion or nutrition systems.

References

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

3. National Center for Biotechnology Information. (n.d.). PubChem compound summary: Thiamine. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Thiamine

4. National Center for Biotechnology Information. (n.d.). DailyMed: Thiamine hydrochloride injection labeling. https://dailymed.nlm.nih.gov/dailymed/

5. United States Pharmacopeia. (2023). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

6. European Medicines Agency. (n.d.). Excipients in the label and package leaflet of medicinal products for human use. https://www.ema.europa.eu/_en/human-regulatory-overview/marketing-authorisation/product-information-requirements/excipients-labelling-package-leaflet